Amalgamated Bank Grows Stock Holdings in Agilent Technologies, Inc. (NYSE:A)

Amalgamated Bank lifted its holdings in Agilent Technologies, Inc. (NYSE:A) by 3.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,060 shares of the medical research company’s stock after purchasing an additional 1,862 shares during the quarter. Amalgamated Bank’s holdings in Agilent Technologies were worth $9,066,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of A. Vanguard Group Inc. increased its holdings in Agilent Technologies by 18.2% in the 1st quarter. Vanguard Group Inc. now owns 29,884,345 shares of the medical research company’s stock worth $4,348,471,000 after buying an additional 4,605,228 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Agilent Technologies by 13.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 8,542,054 shares of the medical research company’s stock valued at $1,242,956,000 after purchasing an additional 1,042,926 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Agilent Technologies by 5.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 15,064,660 shares of the medical research company’s stock worth $1,952,832,000 after buying an additional 809,149 shares during the last quarter. Champlain Investment Partners LLC acquired a new stake in shares of Agilent Technologies in the first quarter worth approximately $61,218,000. Finally, Marshall Wace LLP boosted its holdings in Agilent Technologies by 48.6% in the 2nd quarter. Marshall Wace LLP now owns 957,128 shares of the medical research company’s stock valued at $124,073,000 after purchasing an additional 313,155 shares during the last quarter.

Agilent Technologies Stock Up 0.5 %

Agilent Technologies stock opened at $140.41 on Wednesday. The firm has a market capitalization of $40.34 billion, a P/E ratio of 29.13, a P/E/G ratio of 6.02 and a beta of 1.07. The company has a current ratio of 1.78, a quick ratio of 1.37 and a debt-to-equity ratio of 0.36. Agilent Technologies, Inc. has a twelve month low of $104.09 and a twelve month high of $155.35. The stock’s fifty day simple moving average is $139.70 and its 200-day simple moving average is $138.18.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.06. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter in the prior year, the business earned $1.43 EPS. Agilent Technologies’s revenue was down 5.6% on a year-over-year basis. As a group, equities analysts expect that Agilent Technologies, Inc. will post 5.24 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 23rd. Shareholders of record on Tuesday, October 1st were given a $0.236 dividend. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date was Tuesday, October 1st. Agilent Technologies’s dividend payout ratio is presently 19.50%.

Insider Activity

In related news, CEO Padraig Mcdonnell sold 1,958 shares of the business’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total transaction of $283,910.00. Following the completion of the transaction, the chief executive officer now owns 24,118 shares in the company, valued at approximately $3,497,110. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, SVP Dominique Grau sold 9,990 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the completion of the sale, the senior vice president now owns 40,011 shares in the company, valued at approximately $5,801,595. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total transaction of $283,910.00. Following the completion of the transaction, the chief executive officer now owns 24,118 shares of the company’s stock, valued at approximately $3,497,110. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,995 shares of company stock worth $1,739,510.

Analyst Ratings Changes

Several analysts have recently commented on the stock. TD Cowen lifted their price target on shares of Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $151.00 price target on shares of Agilent Technologies in a research note on Monday, August 26th. UBS Group raised their price objective on Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a research report on Thursday, August 22nd. Barclays boosted their price objective on shares of Agilent Technologies from $135.00 to $145.00 and gave the company an “underweight” rating in a report on Tuesday, October 15th. Finally, Citigroup lifted their price target on shares of Agilent Technologies from $150.00 to $165.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Agilent Technologies currently has a consensus rating of “Moderate Buy” and an average target price of $144.36.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.